NCT04592484 - A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 15, 2020

Primary Completion Date

August 3, 2022

Study Completion Date

December 23, 2022

Conditions

Advanced Solid Tumor

Interventions

BIOLOGICAL

CDK-002

CDK-002 administered intratumorally

Trial Locations (8)

Columbia University/CUMC, New York

University of Pennsylvania, Philadelphia

NEXT Oncology, San Antonio

Honor Health, Scottsdale

The Beatson West of Scotland Cancer Centre/ Gartnavel General Hospital, Glasgow

Oxford University Hospitals NHS Trust, Headington

The Royal Marsden Hospital, London

The Christie NHS Foundation Trust, Manchester